Last reviewed · How we verify
B&A Therapeutics — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- China National Center for Cardiovascular Diseases · 1 shared drug class
- Ferrer Internacional S.A. · 1 shared drug class
- Heart Care Foundation · 1 shared drug class
- Instituto de Investigación Sanitaria Aragón · 1 shared drug class
- Jose J Zaragoza, MD MSc · 1 shared drug class
- Lakeland Regional Health Systems, Inc. · 1 shared drug class
- Aspirus Heart and Vascular Institute-Research and Education · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for B&A Therapeutics:
- B&A Therapeutics pipeline updates — RSS
- B&A Therapeutics pipeline updates — Atom
- B&A Therapeutics pipeline updates — JSON
Cite this brief
Drug Landscape (2026). B&A Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/b-a-therapeutics. Accessed 2026-05-16.